We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases

Press releases

Novasep announces 2016 financial results

Novasep announces 2016 financial results

31 May 2017

Sales are up 3.5% at 271 M€
EBITDA is stable at 28 M€


Novasep appoints Xavier de Saint Guilhem as Chief Financial Officer

Novasep appoints Xavier de Saint Guilhem as Chief Financial Officer

07 Mar 2017

CFO appointment comes as the company gets ready for the next phase of its growth strategy


Novasep opens €11M new antibody-drug conjugate (ADC) bioconjugation unit

Novasep opens €11M new antibody-drug conjugate (ADC) bioconjugation unit

23 Feb 2017

ADCs, used in innovative treatments against cancer, will be produced in Le Mans, France to serve international markets


Novasep Invests in a €27m Viral Vector Production Facility

Novasep Invests in a €27m Viral Vector Production Facility

13 Feb 2017

The strategic investment supports the growing demand for development and commercial phase production of viral-vector based therapies


Three Novasep custom manufacturing sites renew FDA approval in 2016

Three Novasep custom manufacturing sites renew FDA approval in 2016

20 Dec 2016

Successful FDA inspections confirm Novasep’s longstanding reputation in maintaining
quality assurance systems fully compliant with the highest world standards


Novasep sells U.S. subsidiary TangenX Technology Corporation, innovator in tangential flow filtration for biopharmaceuticals

VRI, ANRS and Novasep sign an agreement for the cGMP manufacture of two experimental vaccines for the prevention and treatment of HIV-1/AIDS

VRI, ANRS and Novasep sign an agreement for the cGMP manufacture of two experimental vaccines for the prevention and treatment of HIV-1/AIDS

24 Nov 2016

Two candidate vaccines targeting dendritic cells have been developed at the Vaccine Research Institute (VRI), and their manufacture under cGMP guidelines will permit the set-up of future clinical trials in humans.


Novasep and Japanese agent AR Brown extend partnership

Novasep and Japanese agent AR Brown extend partnership

17 Nov 2016

Stronger local representation in growing Japanese biopharma market will improve Novasep’s capacity to equip and service Japanese clients



NOVASEP ANNOUNCES THE SUCCESS OF ITS REFINANCING

26 Oct 2016

- Successful outcome of Exchange Offer and Consent Solicitation
- Participation of 96.26% of the principal amount of Existing Notes held by holders other than Novasep or its Affiliates



You can stay on this page and select more documents or you can directly download the brochure(s) you selected
Give us your feedback!